Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2025 08:30 ET | Source: RenovoRx, Inc.

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are...
December 11, 2024 08:00 ET | Source: RenovoRx, Inc.

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research...
December 10, 2024 08:00 ET | Source: RenovoRx, Inc.

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...
December 05, 2024 08:00 ET | Source: RenovoRx, Inc.

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath of...
November 20, 2024 08:45 ET | Source: RenovoRx, Inc.

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical...
November 14, 2024 08:00 ET | Source: RenovoRx, Inc.

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
September 25, 2024 08:30 ET | Source: RenovoRx, Inc.

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a...
September 19, 2024 08:30 ET | Source: RenovoRx, Inc.

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
August 27, 2024 08:30 ET | Source: RenovoRx, Inc.

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
August 14, 2024 08:30 ET | Source: RenovoRx, Inc.

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout...